Dorsey Wright & Associates Boosts Position in Abivax SA Sponsored ADR $ABVX

Dorsey Wright & Associates boosted its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 41.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,452 shares of the company’s stock after acquiring an additional 6,832 shares during the period. Dorsey Wright & Associates’ holdings in Abivax were worth $2,611,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of ABVX. Nan Fung Trinity HK Ltd. grew its holdings in Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after buying an additional 12,000 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in shares of Abivax in the fourth quarter worth $1,247,000. Hudson Bay Capital Management LP acquired a new stake in Abivax in the 3rd quarter valued at $7,731,000. Tudor Investment Corp ET AL purchased a new stake in shares of Abivax during the 3rd quarter valued at about $2,792,000. Finally, Brummer Multi Strategy AB purchased a new stake in shares of Abivax during the fourth quarter valued at approximately $1,939,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Price Performance

NASDAQ ABVX opened at $136.65 on Friday. The firm has a market cap of $10.90 billion, a P/E ratio of -26.23 and a beta of 0.87. The stock’s 50-day moving average is $116.97 and its two-hundred day moving average is $118.47. Abivax SA Sponsored ADR has a fifty-two week low of $9.86 and a fifty-two week high of $148.83.

Abivax (NASDAQ:ABVX) last announced its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on ABVX. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and upped their price target for the company from $108.00 to $158.00 in a report on Tuesday, June 30th. Truist Financial raised their price target on Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Barclays lifted their price objective on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Finally, Morgan Stanley reduced their price target on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, June 2nd. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $148.54.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.